Argos Wealth Advisors LLC Takes Position in Bristol Myers Squibb Company $BMY

Argos Wealth Advisors LLC purchased a new stake in Bristol Myers Squibb Company (NYSE:BMY) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 11,600 shares of the biopharmaceutical company’s stock, valued at approximately $626,000.

Other large investors have also added to or reduced their stakes in the company. Brighton Jones LLC increased its stake in shares of Bristol Myers Squibb by 33.4% in the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after acquiring an additional 4,935 shares in the last quarter. Sivia Capital Partners LLC increased its stake in shares of Bristol Myers Squibb by 59.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock valued at $346,000 after acquiring an additional 2,786 shares in the last quarter. United Bank increased its stake in shares of Bristol Myers Squibb by 15.0% in the 2nd quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock valued at $1,164,000 after acquiring an additional 3,277 shares in the last quarter. Marshall Wace LLP bought a new stake in Bristol Myers Squibb during the 2nd quarter valued at $221,000. Finally, Nebula Research & Development LLC bought a new stake in Bristol Myers Squibb during the 2nd quarter valued at $405,000. Institutional investors own 76.41% of the company’s stock.

Insider Activity

In other news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the sale, the executive vice president directly owned 159,248 shares of the company’s stock, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Price Performance

Shares of NYSE:BMY opened at $56.46 on Wednesday. The company’s 50-day moving average is $58.95 and its 200 day moving average is $55.16. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. The company has a market capitalization of $115.30 billion, a P/E ratio of 15.86, a price-to-earnings-growth ratio of 0.16 and a beta of 0.26. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. The company had revenue of $11.49 billion for the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period in the previous year, the firm earned $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities research analysts forecast that Bristol Myers Squibb Company will post 6.3 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd were issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.5%. The ex-dividend date of this dividend was Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 70.79%.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb struck a large collaboration and licensing agreement with Hengrui Pharma covering 13 early-stage programs, including oncology, hematology, and immunology assets, which could strengthen the company’s pipeline and support future growth. Article Title
• Positive Sentiment: The deal includes substantial upfront and future milestone payments, signaling a meaningful commitment to the partnership and possible long-term value creation for Bristol Myers Squibb. Article Title
• Neutral Sentiment: Bristol Myers Squibb also reported that shareholders approved board and compensation matters, which appears routine and is unlikely to be a major driver of the stock today. Article Title
• Neutral Sentiment: One headline noted BMY shares had fallen for a seventh consecutive session before the latest strategic deal news, highlighting recent weakness that the Hengrui announcement may help offset. Article Title

Wall Street Analyst Weigh In

A number of analysts have commented on BMY shares. Cantor Fitzgerald boosted their price target on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the company a “neutral” rating in a research note on Wednesday, April 8th. Barclays began coverage on shares of Bristol Myers Squibb in a research note on Thursday, February 19th. They set an “overweight” rating and a $75.00 price target for the company. HSBC raised their target price on Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a report on Tuesday, March 17th. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Sunday, April 19th. Finally, Piper Sandler restated an “overweight” rating and issued a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Eight analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $61.31.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.